Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Troxacitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 known ✓ | P09884 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.56 |
| ▸ | ALB | P02768 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.56 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.56 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MTOR | P42345 | 1/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.49 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.49 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.49 |
| ▸ | POLG | P54098 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Troxacitabine SCHEMBL1844439 | 0.95 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL1026148 | 0.95 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL1026150 | 0.95 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL6424800 | 0.95 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL1653267 | 0.95 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL18548 | 0.95 | LMNA (0.60) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL22285889 | 0.94 | LMNA (0.59) | LMNAPDE3ACACNA1FALBMAPT | |
| Troxacitabine SCHEMBL7560355 | 0.91 | POLG (0.59) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL31347648 | 0.84 | LMNA (0.59) | LMNAPDE3ACACNA1FALBMAPT | |
| SCHEMBL13770328 | 0.84 | LMNA (0.52) | LMNAPDE3ACACNA1FALBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109069509-A | Combination therapy of phosphoramidate prodrugs of sorafenib or regorafenib and troxacitabine | 麦迪维尔股份公司 | 2018-12-21 | — | — | CN | claimed |
| EP-4135849-B1 | MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER | MEDIVIR AB (SE) | 2025-03-19 | — | — | EP | disclosed |
| EP-3423061-B1 | COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND A PHOSPHORAMIDATE PRODRUG OF TROXACITABINE | MEDIVIR AB (SE) | 2024-08-07 | — | — | EP | disclosed |
| US-20240024342-A1 | MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER | MEDIVIR AB (SE) | 2024-01-25 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-111956646-B | Combination therapy of sorafenib or regorafenib with phosphoramidate prodrugs of troxacitabine | 麦迪维尔股份公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| EP-4135849-A1 | MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER | Medivir Aktiebolag (SE) | 2023-02-22 | — | — | EP | disclosed |
| US-10456413-B2 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | MEDIVIR AKTIEBOLAG (SE) | 2019-10-29 | — | — | US | disclosed |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2019-07-02 | — | — | US | disclosed |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2019-04-04 | — | — | US | disclosed |
| US-20190091246-A1 | COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND A PHOSPHORAMIDATE PRODRUG OF TROXACITABINE | MEDIVIR AKTIEBOLAG (SE) | 2019-03-28 | — | — | US | disclosed |
| EP-3423061-A1 | COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND A PHOSPHORAMIDATE PRODRUG OF TROXACITABINE | Medivir Aktiebolag (SE) | 2019-01-09 | — | — | EP | disclosed |
| CN-109069509-A | Combination therapy of phosphoramidate prodrugs of sorafenib or regorafenib and troxacitabine | 麦迪维尔股份公司 | 2018-12-21 | — | — | CN | disclosed |
| US-10144750-B2 | Dioxolane analogues of cytidine for the treatment of cancer | MEDIVIR AB (SE) | 2018-12-04 | — | — | US | disclosed |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-09-21 | — | — | US | disclosed |
| EP-3186244-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2017-07-05 | — | — | EP | disclosed |
| WO-2016030335-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2016-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091246-A1 | COMBINATION THERAPY WITH SORAFENIB OR REGORAFENIB AND A PHOSPHORAMIDATE PRODRUG OF TROXACITABINE | SLC10A1, BRAF, HCCS | POLA1 2666/4885LMNA 2938/4885PDE3A 4483/4885 |
| US-20190100541-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | POLA1 1235/4885LMNA 2854/4885PDE3A 3450/4885 |
| US-10144750-B2 | Dioxolane analogues of cytidine for the treatment of cancer | NT5C, ADORA3, ADORA1 | POLA1 450/4885LMNA 2548/4885PDE3A 1561/4885 |
| US-20240024342-A1 | MIV-818/LENVATINIB COMBINATION THERAPY FOR LIVER CANCER | MET, MOK, MAPK8 | POLA1 2943/4885LMNA 3763/4885PDE3A 4145/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | POLA1 1226/4885LMNA 3107/4885PDE3A 3478/4885 |
| US-20170267705-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, NT5C, DUT | POLA1 943/4885LMNA 2855/4885PDE3A 2859/4885 |
| US-10336780-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NT5C | POLA1 1210/4885LMNA 3050/4885PDE3A 3359/4885 |
| US-10456413-B2 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | SLC10A1, BRAF, HCCS | POLA1 2666/4885LMNA 2938/4885PDE3A 4483/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | POLA1 1256/4885LMNA 3139/4885PDE3A 3429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.